Candida glabrata antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Candida glabrata antibodies pairs and antigen for animal health (animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease Candidiasis) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Multiple species disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P269-Ag01	Recombinant Candida glabrata protein	$3090.00
GMP-VT-P269-Ab01	Anti-Candida glabrata mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P269-Ab02	Anti-Candida glabrata mouse monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P269-Ag01
Product Name	Recombinant Candida glabrata protein
Pathogen	Candida glabrata
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Candida glabrata antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Candida glabrata level test of animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease with Candidiasis.
Tag	His
Product description	Recombinant Candida glabrata proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P269-Ab01,GMP-VT-P269-Ab02
Pathogen	Candida glabrata
Product Name	Anti-Candida glabrata mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Candida glabrata antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Candida glabrata antibodies in Candida glabrata level test of animal Cat/Feline, Dog/Canine, Rabbit, Bovines/Cattle, Equine/Horse, Ovines/Sheep, Caprine/Goat, Swine/Porcine/Pig infectious disease with Candidiasis.
Product description	Anti-Candida glabrata mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Candida glabrata antibodies./td>
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen

Candida glabrata is a type of yeast-like fungus which is a part of the normal human microbiota of the skin and mucous membranes. It is an opportunistic pathogen, meaning that it can cause infection in individuals who are immunocompromised, such as those undergoing chemotherapy or with HIV/AIDS. Although Candida glabrata infections are less common than those caused by other Candida species such as C. albicans, it is becoming increasingly prevalent and can lead to severe infection, especially in healthcare settings.

Classification:

Candida glabrata belongs to the fungi kingdom, phylum Ascomycota. This pathogen is a eukaryotic organism, meaning that its genetic material is contained within a nucleus inside a membrane-bound cell. Similar to other Candida species, Candida glabrata is a unicellular organism that primarily reproduces through asexual budding.

Pathogenicity:

Several factors contribute to the pathogenicity of Candida glabrata, including its ability to adhere to host tissues, evade the host immune system, and develop antifungal drug resistance.

Candida glabrata's adherence to host tissues is mainly accomplished through its surface proteins such as Hwp1, Ece1, and Als3. These proteins allow the organism to bind to host cells, resist mechanical clearance, and invade host tissues leading to disease. Candida glabrata can also produce a biofilm, which is a protective matrix of extracellular polymeric substances that helps to maintain the organism's attachment to surfaces and further protect it from antifungal agents and the host immune response.

Hosts and Diseases:

Candida glabrata primarily infects immunocompromised individuals, such as those with HIV/AIDS, undergoing chemotherapy, organ transplant recipients, and neonates. The most common clinical manifestation of Candida glabrata infection is bloodstream infection, which can cause sepsis, a life-threatening condition, especially in the elderly population. Other infections caused by Candida glabrata include urinary tract infections, peritonitis, endocarditis, meningitis, and wound infections.

Diagnosis:

Candida glabrata infections can be difficult to diagnose as they share similar symptoms with other Candida species. Proper diagnosis involves a combination of clinical, laboratory, and radiological assessments. Standard diagnostic tests include blood culture, urine culture, and tissue culture. Additionally, molecular techniques, such as polymerase chain reaction (PCR) and DNA sequencing, are commonly employed for identifying Candida glabrata. These methods target specific regions within fungal genes or the internal transcribed spacer (ITS) of rRNA gene clusters and provide an accurate, timely diagnosis. ELISA-based methods can also be used for detecting the presence of Candida glabrata-specific proteins.

Treatment:

Antifungal agents such as azoles, echinocandins, and polyenes are used for the treatment of Candida glabrata infection. However, due to the increasing prevalence of drug resistance, some strains of Candida glabrata can be resistant to antifungal agents, making treatment challenging. Combination therapy, surgical intervention, and long-term suppressive therapy can also be considered.

In conclusion, Candida glabrata is an opportunistic pathogen that causes infections in immunocompromised individuals. It is becoming increasingly prevalent in healthcare settings and can lead to severe infection. Proper diagnosis and treatment are essential for managing Candida glabrata infections, which can be challenging due to the pathogen's ability to develop antifungal drug resistance.

About GDU